Reversion of Human Glioblastoma Malignancy by U1 Small Nuclear RNA/Ribozyme Targeting of Scatter Factor/Hepatocyte Growth Factor and c-met Expression
Roger Abounader,
Srikanth Ranganathan,
Bachchu Lal,
Kevin Fielding,
Adam Book,
Hal Dietz,
Peter Burger,
John Laterra
Affiliations of authors: R.
Abounader, A. Book (Department of Neuroscience and Kennedy Krieger Research Institute), S.
Ranganathan, K. Fielding (Kennedy Krieger Research Institute), B. Lal
(Department of Neurology and Kennedy Krieger Research Institute), H.
Dietz (Institute of Medical Genetics and Howard Hughes Medical
Institute), P. Burger (Department of Pathology), J. Laterra
(Departments of Neuroscience, Oncology, and Neurology and Kennedy
Krieger Research Institute), The Johns Hopkins University School of
Medicine, Baltimore, MD.
Correspondence to: John Laterra, M.D., Ph.D., Kennedy
Krieger Research Institute, 707 N. Broadway, Baltimore, MD 21205 (e-mail: laterra{at}kennedykrieger.org).
 |
ABSTRACT
|
---|
BACKGROUND: Expression of scatter factor (SF), also known
as hepatocyte growth factor (HGF), and its receptor, c-met, is often
associated with malignant progression of human tumors, including
gliomas. Overexpression of SF/HGF in experimental gliomas enhances
tumorigenicity and tumor-associated angiogenesis (i.e., growth of new
blood vessels). However, the role of endogenous SF/HGF or c-met
expression in the malignant progression of gliomas has not been
examined directly. In this study, we tested the hypothesis that human
glioblastomas can be SF/HGFc-met dependent and that a reduction in
endogenous SF/HGF or c-met expression can lead to inhibition of tumor
growth and tumorigenicity. METHODS: Expression of the SF/HGF
and c-met genes was inhibited by transfecting glioblastoma cells with
chimeric transgenes consisting of U1 small nuclear RNA, a hammerhead
ribozyme, and antisense sequences. The effects of reduced SF/HGF and
c-met expression on 1) SF/HGF-dependent induction of immediate
early genes (c-fos and c-jun), indicative of signal transduction; 2)
anchorage-independent colony formation (clonogenicity), an in
vitro correlate of solid tumor malignancy; and 3) intracranial
tumor formation in immunodeficient mice were quantified. Statistical
tests were two-sided. RESULTS: Introduction of the transgenes
into glioblastoma cells reduced expression of the SF/HGF and c-met
genes to as little as 2% of control cell levels.
Reduction in c-met expression specifically inhibited SF/HGF-dependent
signal transduction (P<.01). Inhibition of SF/HGF or c-met
expression in glioblastoma cells possessing an SF/HGFc-met autocrine
loop reduced tumor cell clonogenicity (P = .005 for SF/HGF and
P= .009 for c-met) and substantially inhibited tumorigenicity
(P<.0001) and tumor growth in vivo
(P<.0001). CONCLUSIONS: To our knowledge,
this is the first successful inhibition of SF/HGF and c-met expression
in a tumor model directly demonstrating a role for endogenous SF/HGF
and c-met in human glioblastoma. Our results suggest that targeting the
SF/HGFc-met signaling pathway may be an important approach in
controlling tumor progression.
 |
INTRODUCTION
|
---|
Scatter factor (SF), also known as
hepatocyte growth factor (HGF), is a multifunctional growth factor that
plays a role in the regulation of cell growth, cell motility,
morphogenesis, and angiogenesis(16). The only known
receptor for SF/HGF is the c-met proto-oncogene product, a
transmembrane tyrosine kinase receptor (7,8). SF/HGF and c-met
are found in a wide variety of normal human tissues. SF/HGF is mainly
expressed and secreted by a multitude of mesenchymally derived cells,
whereas c-met messenger RNA (mRNA) and protein are detected in the
epithelium of almost all tissues (9,10). These expression
patterns are consistent with the paracrine role of SF/HGF and c-met in
developmental mesenchymalepithelial interactions, such as in
branching morphogenesis of liver and breast (1012). In
addition, normal to high levels of SF/HGF and c-met are found in
several neoplastic human tissues (9,13), where the
SF/HGFc-met signaling pathway is thought to play a role in
oncogenesis and malignant tumor progression (1315).
Glioblastoma multiforme is the most common and most malignant glial neoplasm. Despite
very aggressive treatment, these malignant gliomas are associated with an average life expectancy
of only 9 months. The formation and malignant progression of human gliomas are complex
processes and involve genetic mutations, chromosomal multiploidy, and aberrant epigenetic
influences of multiple mitogens and angiogenic factors. Several studies (14,16-18) have shown that human gliomas express SF/HGF and c-met and that expression
levels are associated with malignant progression. In addition, SF/HGF gene transfer to
glioblastoma cells enhances tumorigenicity, tumor growth, and tumor-associated angiogenesis in vivo(19,20). While these correlative and gain-of-function
findings are consistent with a role for SF/HGFc-met signaling in the malignancy of
gliomas and other tumors, these findings do not definitely demonstrate a dependency of tumor
growth on this signaling pathway. Specifically, the effects of reducing the expression of
endogenous SF/HGF or c-met on the malignancy of human glioblastomas, indeed on the
malignancy of any tumor, have not been explored.
In this article, we have used a novel chimeric U1 small nuclear RNA (U1snRNA), ribozyme,
and antisense construct to inhibit SF/HGF and c-met gene expression in human glioblastoma cells
possessing an autocrine SF/HGFc-met loop (U-87 MG) and in human glioblastoma cells
expressing c-met but not SF/HGF (U-373 MG). Then we studied the effects of this inhibition on
the malignant phenotype of these human glioblastoma cell lines in vitro and in vivo.
 |
MATERIALS AND METHODS
|
---|
Constructs. The parent vector pZeoU1EcoSpe used in this study and referred to as
pU1 was derived from wild-type U1snRNA as previously described (21).
The U1snRNA, which constitutes the framework of the construct, is an essential component of
the spliceosome complex and is stable and abundant in the nucleus of mammalian cells.
Ribozymes are autocatalytic RNA structures that cleave their targets in a site-specific manner.
The hammerhead ribozyme used in this construct cleaves the RNA at the GUC consensus
sequence. It is flanked by two antisense sequences that determine the specificity of the targeted
RNA by binding to their complementary sequences. Four complementary pairs of oligonucleotides
that encode SF/HGF and c-met antisense, as well as the 22 nucleotides of the hammerhead
ribozyme, were synthesized and annealed at 40 °C. The antisense/ribozyme sequences were
chosen so that the ribozyme cleaves the targeted mRNA immediately 3' of the GUC
ribozyme cleavage consensus sequence, at positions 547 and 701 of the human SF/HGF mRNA
and at positions 292 and 560 of the human c-met mRNA (Fig. 1,
A). The
antisense/ribozyme duplexes were ligated into pU1 at the EcoRI and SpeI sites
to create pU1/SF and pU1/met vectors (Fig. 1
, A). All ligation junctions
were sequenced to verify the orientation of the inserts. The sequence of the resulting chimeric
RNA was analyzed with the use of a program that predicts RNA structure (22) so that we could ensure a maximal preservation of the U1snRNA stem loops, the
ribozyme secondary structure, and the accessibility of the antisense sequence to the target mRNA
(Fig. 1
, B). The U1snRNA/ribozyme/antisense construct is designated as
U1snRNA/ribozyme throughout the article.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1. A) Schematic representation and sequence of chimeric
constructs used to inhibit scatter factor/hepatocyte growth factor
(SF/HGF) and c-met expression in U-373 MG and U-87 MG human
glioblastoma cells showing antisense (red) and hammerhead
ribozyme (brown) sequences flanked by the U1 small nuclear RNA
(U1snRNA) (green). Sense sequences are shown in blue;
EcoRI and SpeI sequences are shown in black.
Arrows indicate ribozyme cleavage sites on the targeted messenger
RNA (mRNA). B) Representative multifold computer analysis of
secondary structure of U1snRNA/ribozyme/antisense transcript
showing the preservation of U1snRNA loops and few
antisense hydrogen bonds to ensure availability of the antisense
sequence to bind to the targeted mRNA.
|
|
Transfection and screening of U-373 MG/U-87 MG human glioblastoma cells.
Wild-type U-373 MG and U-87 MG glioblastoma cells were transfected with either pU1/met,
pU1/SF, or pU1 (as a control), with the use of the polycationic reagent Lipofectamine (15
µg/mL; Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD).
Control-transfected and U1snRNA/ribozyme-transfected cell lines were treated identically with
regard to transfection conditions and maintenance in selection medium. Transfected cell lines were
selected in the presence of 100 µg/mL Zeocin (Invitrogen Corp., Carlsbad, CA). The cell
lines transfected with pU1 (control), pU1/SF, or pU1/met were screened for SF/HGF or c-met
mRNA and protein levels by northern blotting and immunoblotting as described below. The
screening was repeated two to four times, and the mean values of SF/HGF or c-met mRNA
relative to glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA were calculated for each
cell line. Cell lines with 89% or more inhibition of targeted mRNA were designated
knockdown (suffix "KD") to describe the nearly complete inhibition of targeted
gene expression. For this study, we selected two U-373 MG control-transfected (suffix
"CT") cell lines designated U373-CT (C1 and C2), three U-373 MG c-met
knockdown cell lines designated U373-MET-KD (292-1, 560-1, and 560-2), two U-87 MG
control-transfected cell lines designated U87-CT (C3 and C4), three SF/HGF knockdown cell
lines designated U87-SF-KD (547-1, 547-2, and 701-1), and three c-met knockdown cell lines
designated U87-MET-KD (292-2, 292-3, and 560-3).
Induction of expression of c-met, c-fos, and c-jun. U373-CT and U373-MET-KD
cells were grown to 70%-75% confluence on 10-cm dishes and pretreated with
media containing 0.1% fetal bovine serum for 18-24 hours. The cells were then exposed to
10 ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma Chemical Co., St. Louis, MO), 10
ng/mL SF/HGF (a gift from Genentech, Inc., La Jolla, CA), or 10% fetal bovine serum.
Control cells received solvent only. For c-met induction, cells were treated with PMA for 6 hours
and with SF/HGF or serum for 8 hours before RNA isolation. For c-fos and c-jun expression,
cells were treated with each agonist for 30 minutes before RNA extraction.
Northern blot hybridization. RNA was isolated with the use of the RNeasyTM
Mini Kit (QIAGEN, Hilden, Germany), following the manufacturer's directions. Northern
blot analysis was performed with modifications of a previously reported procedure (23). In brief, 10 µg of total RNA was subjected to electrophoresis on a 1%
agarose gel and transferred to a Nytran membrane (Schleicher & Schuell, Dassel, Germany).
Hybridization was performed with complementary DNA (cDNA) probes for the coding regions of
human SF/HGF (2.2 kilobases [kb]), c-met (1.3 kb), c-fos (1.35 kb), and c-jun (1.5
kb), which were labeled with [32P]deoxycytidine triphosphate
(Amersham, Buckinghamshire, U.K.) by use of a random priming kit (Boehringer Mannheim
GmbH, Mannheim, Germany). The membranes were exposed to the phosphor-imager screen
(Fuji, Tokyo, Japan) and to high-performance chemiluminescence film (Amersham). The signal
was quantified by densitometry and by use of the Bio-Imaging analyzer BAS 2500 (Fujifilm,
Tokyo, Japan). All blots were reprobed with GAPDH cDNA (1.9 kb) to control for RNA loading
and transfer errors, and the results were normalized to GAPDH mRNA levels.
Immunoblotting. The SF/HGF protein secreted in conditioned media was assessed as
described previously (24). The conditioned media were collected from
70% confluent U87-CT and U87-SF-KD cells (cultured for 24 hours in serum-free media)
and were concentrated 30-fold with the use of Centriplus 10 membranes (Millipore Corp.,
Bedford, MA) before analysis. The c-met protein was measured in total cell extracts from
U373-CT, U373-MET-KD, U87-CT, and U87-MET-KD cell lines. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and immunoblotting were performed essentially
according to the method of Towbin et al. (25). For SF/HGF, the amount
of protein loaded in each lane was normalized to the number of cells and electrophoretically
separated under nonreducing conditions. For c-met, 20 µg of total cell protein was loaded
per lane and separated under reducing conditions. Proteins were electrophoretically transferred
onto a nitrocellulose membrane that was incubated subsequently with anti-SF/HGF at a 1 : 1000
dilution (a gift from Dr. E. Rosen, Long Island Jewish Medical Center, New Hyde Park, NY) or
with 1 µg/mL human anti-c-met polyclonal immunoglobuin G (IgG) (Santa Cruz
Biotechnology, Santa Cruz, CA). After being washed (25), the
membranes were reacted with horseradish peroxidase (HRP)-conjugated IgG (Jackson
ImmunoResearch, West Grove, PA) at a 1 : 1000 dilution. Bound antibodies were then visualized
with the use of an ECL western blotting detection kit (Amersham), and the digitized images were
quantitatively analyzed by densitometry (Molecular Dynamics, Sunnyvale, CA).
Colony formation in soft agar. Anchorage-independent tumor cell proliferation was
assessed by use of colony formation in soft agar according to the method of Leone et al. (26). U-87 MG and U-373 MG knockdown or control-transfected cells
were plated (10 000 cells per well) and incubated at 37 °C in 5% CO2-95% O2 in minimum essential medium containing 1 mM
sodium pyruvate, 0.1 mM nonessential amino acids, and 1% fetal bovine serum.
After 2 weeks, the cells were stained blue with Wright's solution, and the number of
colonies larger than 100 µm in diameter (U-87 MG-derived cell lines) or 75 µm in
diameter (U-373 MG-derived cell lines) were determined by use of computer-assisted image
analysis (19).
Tumor formation in vivo. Confluent monolayers of control-transfected and
SF/HGF or c-met knockdown cells were trypsinized and resuspended in serum-free medium at 5
x 105 cells/µL. The cells (2 µL) were injected intracranially into the
caudate/putamen by use of a 26-gauge beleveled-tip syringe as previously described (19). At 3 weeks after implantation for U87-derived tumors and at 12 weeks after
implantation for U373-derived tumors, the mice were killed by decapitation, and their brains were
dissected and rapidly frozen on dry ice. Cryostat sections (30 µm thick) were fixed in
4% paraformaldehyde and stained with hematoxylin-eosin. The maximal tumor
cross-sectional area was determined by computer-assisted image analysis, and the tumor volume
was estimated with the use of the following formula: volume = (square root of maximal
tumor cross-sectional area)3 (27). Mice received injections
of either one of the following cell lines: two control-transfected U-373 MG, three c-met
knockdown U-373 MG, two control-transfected U-87 MG, three c-met knockdown U-87 MG, or
three SF/HGF knockdown U-87 cell lines. Each group contained six mice, for a total of 78 mice
receiving injections. The animals were anesthetized with a mixture of xylazine (0.01 mg/g body
weight; Phoenix Pharmaceuticals, St. Joseph, MO) and ketamine hydrochloride (0.1 mg/g body
weight; Parke-Davis, Morris Plains NJ). All animal manipulations were done in accordance with
The Johns Hopkins University Animal Care and Use Committee.
Determination of proliferation index. The proliferation index was assessed by
immunocytochemistry with monoclonal Ki-67 antibody as described before (28). Briefly, 20-µm thin tissue sections were reacted with primary anti-Ki-67
antibody (DAKO A/S, Glostrup, Denmark) (1 : 100 dilution), washed, and then treated with
HRP-conjugated secondary anti-rabbit IgG (Sigma Chemical Co.). After being washed, the
sections were developed in 3,3'-diaminobenzidine (DAB) (Sigma Chemical Co.) and
stained with hematoxylin-eosin. To quantify proliferative activity, we counted DAB-stained tumor
cells relative to the total number of cells on photomicrographs.
Statistical methods. Data on tumor size and Ki-67 labeling of tumors in vivo
were analyzed with the use of Bonferroni/Dunn multiple comparisons tests. Data on
tumorigenicity were analyzed by two-sided Fisher's exact tests. Data on the in vitro anchorage-independent colony formation of the U373-derived cell lines and U87-derived
cell lines were analyzed by two-sided Student's t test and by Bonferroni/Dunn
multiple comparisons test, respectively. Data for immediate early response gene induction were
analyzed by two-sided Student's t test. All tests were performed with the use of
the Statview 4.0 computer program. Numerical data are expressed as means ± standard
deviation (SD) with degrees of freedom (df) calculated according to the statistical tests
used.
 |
RESULTS
|
---|
Inhibition of SF/HGF and/or c-met gene expression in
glioblastoma cells by chimeric U1snRNA/ribozyme gene transfer. We
have previously shown that the U-87 MG human glioblastoma cell line
expresses both c-met and SF/HGF and that the U-373 MG human
glioblastoma cell line used in this study expresses c-met but not
SF/HGF (14,19,24). U-373 MG and U-87 MG glioblastoma cells
were stably transfected with chimeric U1snRNA/ribozyme constructs
designed to specifically target SF/HGF or c-met or with control plasmid
(Fig. 1
), and clonal cell lines were subsequently screened for SF/HGF
or c-met mRNA by northern blot hybridization. SF/HGF and c-met mRNA
levels in control-transfected cells were very similar and comparable to
mRNA levels in wild-type cells (not shown). The mRNA levels of the
U1snRNA/ribozyme-targeted genes (c-met or SF/HGF) in most knockdown
clones were less than 50% of the mean mRNA levels of
control-transfected cell lines with several clones expressing less than
10% of control levels. No differences were seen in the efficiency of
gene expression knockdown between the different gene sequences targeted
(not shown). SF/HGF and c-met protein levels were assessed in
conditioned media and total cell lysates, respectively, with the use of
immunoblotting. The extent of SF/HGF and c-met protein reduction
generally reflected the extent of mRNA inhibition. The control and
knockdown cell lines selected for subsequent experiments and their
relative levels of c-met and SF/HGF mRNA and protein are shown in Table
1
and Fig. 2.
View this table:
[in this window]
[in a new window]
|
Table 1. Inhibition of scatter factor/hepatocyte growth factor
(SF/HGF) and c-met gene expression in human glioblastoma cells by U1 small nuclear RNA
(U1snRNA)/ribozyme gene transfer*
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2. A) Northern blot analysis of scatter
factor/hepatocyte growth factor (SF/HGF) and c-met expression in U-373
MG and U-87 MG human glioblastoma cells transfected with chimeric U1
small nuclear RNA (U1snRNA)/ribozyme or with control construct showing
strong reduction in messenger RNA levels in knockdown cell lines (KD)
as compared with control transfected cell lines (CT). The complementary
DNA probe encompassing 2.2 kilobases (kb) of the human SF/HGF or 1.3 kb
of the human c-met coding sequence was labeled with 32P and
hybridized with 10 µg of total RNA. Blots were stripped and
reprobed for glyceraldehyde phosphate dehydrogenase (GAPDH) to control
for differences in loading and transfer of RNA. The c-met RNA band is 9
kb long; SF/HGF splicing variants are 6, 3, and 1.3 kb. B)
Immunoblot analysis of SF/HGF and c-met in U-373 MG and U-87 MG
glioblastoma cells showing strong reduction in protein levels in
knockdown clones (KD) as compared with control transfected clones (CT).
Conditioned media (SF/HGF) or total cellular
extract (c-met) was subjected to polyacrylamide gel electrophoresis
and immunoblotted with human anti-SF/HGF or anti-c-met antibody.
Blots show a 190-kilodalton (kd) c-met precursor (upper band)
and a 145-kd c-met receptor (lower band) and a 90-kd SF/HGF
protein.Lanes in blots are representative of two
to four independent analyses and show all clonal cell lines used in
this study (from left to right): C1, C2, 292-1, 560-1, and
560-2; C3, C4, 547-1, 547-2, and 701-1; and C3, C4, 292-2, 292-3, and 560-3.
|
|
Inhibition of c-met induction by U1snRNA/ribozyme. Serum, phorbol esters,
cytokines, and various growth factors that may influence c-met expression levels in vivo
induce c-met gene expression in cultured cells. Thus, an effective knockdown strategy should
inhibit inducible as well as basal c-met expression levels. To assess the efficiency of chimeric
U1snRNA/ribozyme, we examined the effects of two potent inducers of c-met, PMA and serum,
on c-met expression in U373 MG c-met knockdown (U373-MET-KD) and U373 MG
control-transfected (U373-CT) cells. The c-met mRNA levels in U373-CT cells were increased
after treatment of the cells with 10 ng/mL PMA and 10% serum by approximately 10-fold
and sevenfold, respectively, relative to untreated U373-CT cells (Fig. 3)
.
The mRNA levels of c-met after induction by PMA and serum remained approximately 10-fold
lower in U373-MET-KD relative to the treated U373-CT cells (Fig. 3)
.
These data show that the chimeric U1snRNA/ribozyme used in this study efficiently diminishes
target mRNA even under conditions that substantially induce c-met gene transcription.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3. U1 small nuclear RNA (U1snRNA) inhibits inducible c-met
gene expression. This inhibition is shown by the substantially lower
levels of c-met messenger RNA (mRNA) after treatment with 10 ng/mL
phorbol 12-myristate 13-acetate (PMA) and 10% serum in U-373 MG c-met
knockdown glioblastoma (U373-MET-KD) as compared with control
transfected (U373-CT) cell lines. mRNA levels of c-met were determined
by northern blot analysis. Bars represent percent change in
c-met RNA measured by densitometry on film (upper panels) and
normalized to glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA
levels on the same blots (lower panels). All results were
normalized to U373-CT, which was set at 100%. Quantitative data
represent means ± standard deviation of two different control and
two different knockdown clonal cell lines from two experiments (n = 4).
Blots shown are from a representative experiment.
|
|
Inhibition of induction of immediate early response genes by SF/HGF after
U1snRNA/ribozyme c-met knockdown. Activation of c-met results in downstream signaling
events that mediate cell responses to SF/HGF. One of these events is the induction of the
immediate early genes c-fos and c-jun. To determine if U1snRNA/ribozyme c-met knockdown is
sufficient to alter c-met-dependent signal transduction, we examined the induction of c-fos and
c-jun by SF/HGF in U373-CT and U373-MET-KD cell lines. Induction of c-fos/c-jun by PMA
and serum, which is not mediated by the c-met-receptor and, therefore, not expected to be altered
in U373-MET-KD cells, was examined as controls. Treatment of U373-CT cells with PMA (10
ng/mL), SF/HGF (10 ng/mL), and serum (10%) for 30 minutes increased c-fos mRNA
levels by 306% ± 126% (mean ± SD), 140% ±
60%, and 480% ± 82% (Fig. 4,
A),
respectively, and increased c-jun mRNA by 44% ± 22%, 42%
± 16%, and 82% ± 30% (Fig. 4
, B),
respectively, relative to basal levels. PMA and serum increased c-fos mRNA levels in
U373-MET-KD cells, similar to results seen in the U373-CT cells, 236% ±
92% (P = .40 compared with induction in U373-CT cells, with df = 6) and 678% ± 292% (P = .24 compared with
induction in U373-CT cells; df = 6), respectively. In contrast, the increase in
c-fos mRNA levels in response to SF/HGF in U373-MET-KD cells was one fifth (25%
± 9.4%) that in U373-CT cells (P = .009 compared with induction
in U373-CT cells; df = 6) (Fig. 4
, A). PMA and serum
induced c-jun mRNA levels in U373-MET-KD cells by 22% ± 10.8% (P = .13 compared with induction in U373-CT cells; df = 6) and
52% ± 16% (P = .12 compared with induction in U373-CT
cells, df = 6), respectively. In contrast, the levels of c-jun mRNA remained
unchanged after incubation of U373-MET-KD cells with SF/HGF (2% ±
8%; P = .004 compared with induction in U373-CT cells; df
= 6) (Fig. 4
, B). Thus, c-met knockdown statistically significantly
reduced c-fos and c-jun induction by SF/HGF, whereas induction by PMA and serum was not
statistically significantly altered. These data show that U1snRNA/ribozyme-mediated c-met
knockdown specifically inhibits c-met-mediated downstream signal transduction.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4. Knockdown of c-met inhibits c-met-dependent
signal transduction. This inhibition is shown by the substantially
lower levels of c-fos (A) and c-jun (B) messenger RNA
(mRNA) in the U-373 MG c-met knockdown glioblastoma cells (U373-MET-KD)
as compared with control-transfected cells (U373-CT) after treatment
with 10 ng/mL scatter factor/hepatocyte growth factor (SF/HGF) (shown
as SF on fig.). Responses to 10 ng/mL phorbol 12-myristate 13-acetate
(PMA) and 10% serum (SER), which induce c-fos and c-jun in a
c-met-independent manner, were not affected by c-met knockdown
(P>.1). The mRNA levels were determined by northern blot
analysis. Bars represent percent change in mRNA measured by
densitometry on film (upper panels) and normalized to
glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA levels on the same
blots (lower panels). Quantitative data represent means ± SD
of two different control and three different
knockdown clonal cell lines from two experiments (n = 4). Blots shown
are from a representative experiment. Unt. = untreated. P =
.009 in A (c-fos expression) and P = .004 in B
(c-jun expression) (comparing percent
change in SF/HGF-treated U373-CT cells with the percent change in
SF/HGF-treated C-MET-KD cells), two-sided unpaired Student's t tests; degrees of freedom = 6.
|
|
Inhibition of anchorage-independent colony formation by U1snRNA/ribozyme disruption
of the SF/HGF-c-met autocrine loop. Anchorage-independent colony formation, an in
vitro correlate of solid tumor malignancy, was studied in soft agar.
U1snRNA/ribozyme-mediated c-met knockdown had no effect on colony formation in U-373 MG
cells that lack an SF/HGF-c-met autocrine loop (1.3 ± 1.1 colonies per field [mean
± SD] for U373-MET-CT as compared with 1.1 ± 0.8 colonies per field for
U373-MET-KD; P = .87; df = 4). In contrast, colony formation
in U-87 MG cells that normally express both SF/HGF and c-met was decreased 17-fold following
SF/HGF knockdown (21.3 ± 8.1 colonies per field versus 1.2 ± 1.1 colonies per
field; P = .005; df = 4). Anchorage-independent colony
formation was also reduced 11-fold following c-met knockdown (21.3 ± 8.1 colonies per
field versus 1.9 ± 0.9 colonies per field; P = .009; df =
3). These results indicate that U1snRNA/ribozyme-mediated SF/HGF knockdown and c-met
knockdown reduce the malignant phenotype of glioblastomas in vitro by disrupting
autocrine SF/HGF-c-met-dependent cell stimulation.
Inhibition of glioblastoma tumorigenicity in vivo by U1snRNA/ribozyme
disruption of the SF/HGF-c-met autocrine loop. The roles of SF/HGF and c-met on tumor
formation and growth in vivo were studied by implantation of control-transfected and
SF/HGF- and c-met knockdown cell lines into the striatum of immunodeficient mice. In nude
mice, both U373-CT and U373-MET-KD cell lines formed small tumors 12 weeks after
implantation in all animals (0.15 mm3 ± 0.17 mm3 and 0.27
mm3 ± 0.16 mm3, respectively). Tumor sizes did not differ
significantly between the two groups (P = .056; df = 28).
Control-transfected U-87 MG clones formed large tumors (10.0 mm3 ± 8.5
mm3) in all animals. For the U87-SF-KD cell lines, only seven of 18 mice formed
tumors that were 83-fold smaller than those of the controls (P<.0001; df
= 27) (Table 2,
Fig. 5)
. Of 18 mice
receiving injections of U87-MET-KD cells, 14 developed tumors that were one hundredth the size
of controls (P<.0001; df = 27) (Table 2
, Fig.
5
). These results show that the tumorigenicity and growth in vivo of human glioblastoma xenografts that express an autocrine SF/HGF-c-met loop are
substantially inhibited by U1snRNA/ribozyme targeting of SF/HGF or c-met expression.
View this table:
[in this window]
[in a new window]
|
Table 2. Inhibition of in vivo tumorigenicity and tumor
growth by U1 small nuclear RNA/ribozyme-mediated knock-down of scatter factor/hepatocyte
growth factor and c-met gene expression*
|
|

View larger version (140K):
[in this window]
[in a new window]
|
Fig. 5. Scatter factor/hepatocyte growth factor (SF/HGF) and
c-met knockdown inhibits U-87 MG malignancy in vivo. Top
row: Brain sections stained with hematoxylin-eosin, showing
representative xenografts (arrows) obtained from
control-transfected (control) and SF/HGF (SF-KD) or c-met (C-MET-KD)
knockdown U-87 MG cells. Middle row: Photomicrographs suggest
increased differentiation of knockdown tumor cells that appear larger
with lower nuclear-to-cytoplasmic ratios than controls. Bottom
row: Photomicrographs of tumor xenografts immunocytochemically
labeled with Ki-67 that stains proliferating cells (dark
brown). A smaller fraction of cells are labeled in knockdown
relative to control tumors.
|
|
Alteration of glioblastoma histology and cell proliferation index in vivo by
U1snRNA/ribozyme targeting of SF/HGF or c-met. The histology of U87-SF-KD and
U87-MET-KD xenografts differed from that of the controls, which is consistent with a more
differentiated phenotype. Tumors derived from knockdown cell lines were less hypercellular and
consisted of larger cells with lower nuclear-to-cytoplasmic ratios (Fig. 5
).
Tumor cell expression of the nuclear proliferation antigen Mib-1 was measured by
immunocytochemistry with the use of monoclonal anti-Ki-67 antibody. The percentage of cells
positive for Mib-1 defines the growth fraction of a given cell population and correlates with
human glioma malignancy and poor prognosis. In both U87-SF-KD and U87-MET-KD, the
fraction of tumor cells expressing Mib-1 was significantly less than in U87-CT (21.5%
± 5.9%, 21.6% ± 3.0%, and 40.3% ±
5.1%, respectively) (P<.0001; df = 10), which is consistent
with the reduced tumor growth rates in the knockdown cell lines (Fig. 5
).
 |
DISCUSSION
|
---|
To our knowledge, this is the first report of SF/HGF-c-met gene
expression knockdown and its effects on SF/HGF-mediated cell signaling
and tumorigenesis in glioblastoma cells, indeed in any tumor model. We
have combined U1snRNA, ribozyme, and antisense technologies to achieve
a high degree of inhibition of gene expression in the U-373 MG and U-87
MG glioblastoma cells used in this study. The U1snRNA, which
constitutes the framework of the construct, is an essential component
of the spliceosome complex and is stable and abundant in the nucleus of
mammalian cells (29). Important attributes of U1snRNA are its
potent and constitutively active promoter, stable stem loops with a
high GC content, the ability of the unusual trimethylguanosine 5'
cap and Sm protein interactions to signal transport of U1snRNA to the
nucleus (30), and the lack of polyadenylation of mature small
nuclear RNAs, a characteristic that favorably influences transcript
trafficking and localization (31). All of these factors
theoretically contribute to the high expression and stability of
construct-derived regulatory transcripts, especially in the nucleosome
(21). Ribozymes are autocatalytic RNA structures that cleave
their targets in a site-specific manner. The hammerhead ribozyme used
in this construct cleaves the RNA at the GUC consensus sequence. It is
flanked by two antisense sequences that determine the specificity of
the targeted RNA by binding to their complementary sequences. Using a
similar construct, Montgomery and Dietz (21) knocked-out
fibrillin-1 expression in human osteosarcoma cells to levels
undetectable by northern blot analysis. They also showed that
U1/ribozyme RNA specifically accumulates in the cell nuclear
compartment and that inhibition of targeted RNA required the
construct's U1 flanking sequences. The relative contributions of
RNA-RNA duplex formation versus ribozyme action to the degradation of
targeted RNA by this chimeric construct has not been established and is
under active investigation. In our system, basal levels of SF/HGF and
c-met mRNA and protein were lowered to as little as 2% of control
levels. The c-met mRNA levels remained significantly reduced under
conditions of induced gene expression, demonstrating the
effectiveness of the construct in degrading targeted mRNA. The
incomplete knock-out of SF/HGF or c-met expression could be explained
by the inaccessibility of a small pool of targeted mRNA to the chimeric
U1snRNA/ribozyme transcript. Such a mechanism is suggested by our
experimental finding of the same proportional reduction in basal and
induced c-met mRNA in knockdown cells relative to basal and induced
levels in control transfected cells. Another possible explanation is
that glioblastoma cells completely lacking c-met receptors (or SF/HGF
synthesis in cells with an autocrine SF/HGF-c-met loop) are not
viable. The achieved knockdown did, however, lead to significant
phenotypic changes, as evidenced by numerous criteria.
To determine if c-met knockdown affects downstream signal transduction, we examined c-fos
and c-jun induction in U373-MET-KD and U373-CT cells after stimulation of the cells with
SF/HGF. Activation of the c-met receptor was shown to induce expression of immediate early
genes in several cell types and tissues (32) but not previously in
glioblastoma cells. We showed that this is also true for U-373 MG glioblastoma cells and that this
response is strongly reduced (c-fos) or abolished (c-jun) by the U1snRNA/ribozyme, indicating a
significant inhibition of downstream signal transduction after c-met receptor gene knockdown.
Importantly, c-met receptor-independent induction of c-fos and c-jun by PMA and serum was not
affected in U373-MET-KD, demonstrating the specificity of the effects of
U1snRNA/ribozyme-mediated knockdown to c-met-dependent pathways.
A number of previous studies support a role for the SF/HGF-c-met signaling pathway in the
formation and malignant progression of various tumors, including gliomas. This conclusion is
based on 1) the high expression levels of SF/HGF and/or c-met in various tumors and their
correlation with malignancy and poor prognosis (9,14,17,24), 2) the
enhanced tumorigenicity or malignant transformation following overexpression of SF/HGF or
c-met in tumor cells (15,19,20,33,34), and 3) the demonstration that
activating c-met mutations promote tumor formation (35). Recently, Date
et al. (36) reported inhibition of growth of an experimental gallbladder
carcinoma by the systemic administration of a synthetic SF/HGF N-terminal peptide (NK4)
capable of functioning as a SF/HGF antagonist. To date, however, no previous study had
examined the biologic effects of inhibiting endogenous SF/HGF or c-met gene expression in
tumor cells. We hypothesized that the growth of human glioblastomas can be, in part, dependent
on SF/HGF and/or c-met expression and that inhibiting SF/HGF or c-met would decrease their
tumorigenicity and growth rates. We tested this hypothesis by assessing in vitro and in vivo malignancy of SF/HGF and/or c-met knockdown in glioblastoma cells that express
only c-met (U-373 MG) or that express both SF/HGF and c-met (U-87 MG). For control U-373
MG cells, anchorage-independent clonogenicity was low and in vivo tumor formation
was slow relative to control U-87 MG cells that possess an autocrine SF/HGF-c-met loop.
Knockdown of c-met did not significantly alter the malignant phenotype of U-373 MG cells in
vitro or in vivo, indicating that the malignancy of glioblastomas lacking an autocrine
SF/HGF-c-met loop or other paracrine source of SF/HGF cannot be inhibited by targeting tumor
cell c-met receptor expression or function alone. Thus, host-derived SF/HGF from brain or
systemic organs appears to play little, if any, role in the growth of these experimental intracranial
gliomas. In contrast, when the autocrine loop of U-87 MG cells was inhibited,
anchorage-independent clonogenicity, tumorigenicity, and tumor growth rates in vivo
were dramatically reduced. While targeting either SF/HGF or c-met led to a comparable inhibition
in tumor growth rates, greater inhibition of tumorigenicity in vivo resulted from SF/HGF
gene knockdown. This greater in vivo response might be explained by the inhibition of
SF/HGF-stimulated paracrine processes, such as angiogenesis, in addition to the inhibition of
autocrine processes as a result of the SF/HGF knockdown (Fig. 6
).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6. Mechanisms by which scatter factor/hepatocyte growth
factor (SF/HGF) contributes to glioblastoma malignancy. 1 =
Glioblastoma-derived SF/HGF activates glioblastoma cell c-met receptors
resulting in autocrine growth stimulation (19), tumor cell
migration (14), and apoptosis inhibition (41), via
transcription-dependent and/or transcription-independent pathways. 2
= Glioblastoma cell-derived SF/HGF enhances tumor-associated
angiogenesis via paracrine stimulation of vascular endothelial cells
that express c-met receptors (37,20). 3 = c-met activation
may induce glioblastoma cell secretion of other angiogenic/permeability
factors, such as vascular endothelial growth factor (vegf) that
stimulate tumor angiogenesis and increase vessel permeability
(38). 4 = Host-derived SF/HGF may also play an
important role in stimulating tumor growth under certain conditions. While SF/HGF
knockdown in glioblastoma cells inhibits mechanisms 1, 2, and 3, c-met
knockdown inhibits 1 and 3. This model is based on our findings from
the current article and from other published studies as referenced in
the article.
|
|
Suppression of glioblastoma growth by inhibiting SF/HGF and/or c-met is likely to involve
multiple mechanisms (Fig. 6
). Studies show that the establishment of an
SF/HGF-c-met autocrine loop can cause malignant transformation (15,34). In tumor cells that express both SF/HGF and c-met, SF/HGF can activate c-met receptors on
the tumor cell itself and act on c-met receptors present on surrounding tissues, such as vascular
endothelial cells. SF/HGF is a potent angiogenic factor (37), and we
previously reported (20) that SF/HGF gene transfer enhances the growth
of an experimental rat glioma probably by stimulating angiogenesis. SF/HGF can also activate
tumor cell c-met receptors, stimulating various downstream events such as the induction of genes
that affect tumorigenicity, angiogenic factor secretion, tumor growth, and tumor cell migration
and invasion (Fig. 6
). These downstream responses vary, depending on
the target cell type, and include the expression of vascular endothelial growth factor that is a
prominent angiogenic/vascular permeability factor in malignant gliomas (38), matrix-degrading proteases such as plasminogen activators and matrix
metalloproteinases (39,40), and apoptosis-inhibiting factors (41). Knocking down SF/HGF or c-met expression in cells that express an autocrine
loop could result in tumor growth inhibition, in part by reducing the expression of these other
mediators of tumor progression (Fig. 6
). Glioma cells release numerous
other growth factors and cytokines that can initiate reciprocal interactions between tumor cells
and their surrounding normal cellular compartment. Many of these important and complex
interactions would not be expected to be directly affected by the specific U1/ribozyme constructs
used in this study.
In conclusion, we have shown that a chimeric gene made up of U1snRNA, hammerhead
ribozyme, and antisense sequences is very effective in the targeted inhibition of glioblastoma gene
expression, making it a potentially important tool for inhibiting oncogene expression and for gene
therapy in general. To our knowledge, this first report of SF/HGF-c-met gene knockdown in solid
tumors shows that the malignancy of human gliomas can be SF/HGF-c-met dependent and that
inhibiting SF/HGF or c-met expression or function might be of significant therapeutic value in
these extremely aggressive central nervous system neoplasms. Practical approaches that overcome
obstacles of delivering genetic and biological drugs across the blood-brain barrier to invasive glial
neoplasms will need to be available before these and similar therapeutic strategies can be
extrapolated to humans.
 |
NOTES
|
---|
Supported by Public Health Service grants RO1NS32148 (J. Laterra) (National Institute of
Neurological Disorders and Stroke) and RO1AR41135 (H. Dietz) (National Institute of Arthritis
and Musculoskeletal and Skin Diseases), National Institutes of Health, Department of Health and
Human Services; by the Smilow Foundation (H. Dietz); and by the Howard Hughes Medical
Institute.
We thank Drs. Kirby Smith and Jyh-Feng Lu for their helpful discussions and Ms. Angela T.
Williams for help in manuscript preparation.
 |
REFERENCES
|
---|
1
Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M,
Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.[Medline]
2
Weidner KM, Hartmann G, Sachs M, Birchmeier W. Properties
and functions of scatter factor/hepatocyte growth factor and its receptor c-Met. Am J
Respir Cell Mol Biol 1993;8:229-37.[Medline]
3
Vigna E, Naldini L, Tamagnone L, Longati P, Bardelli A, Maina
F, et al. Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET
proto-oncogene. Cell Mol Biol (Noisy-le-grand) 1994;40:597-604.
4
Zarnegar R, Michalopoulos GK. The many faces of hepatocyte
growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 1995;129:1177-80.[Medline]
5
Bladt F, Rietmacher D, Isenmann S, Aguzzi A, Birchmeier C.
Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb
bud. Nature 1995;376:768-71.[Medline]
6
Matsumoto K, Nakamura T. Emerging multipotent aspects of
hepatocyte growth factor. J Biochem (Tokyo) 1996;119:591-600.[Abstract]
7
Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude
G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase
family of growth-factor receptors. Proc Natl Acad Sci U S A 1987;84:6379-83.[Abstract]
8
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE,
Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met
proto-oncogene product. Science 1991;251:802-4.[Medline]
9
Di Renzo MF, Narshimhan RP, Olivero M, Bretti S, Giordano S,
Medico E, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6:1997-2003.[Medline]
10
Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the
c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994;127:1783-7.[Abstract]
11
Schmidt C, Bladt F, Goedcke S, Brinkmann V, Zschiesche W,
Sharpe M, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699-702.[Medline]
12
Uehara Y, Monowa O, Mori C, Shiota K, Kuno J, Noda T, et al.
Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995;373:702-5.[Medline]
13
Jeffers M, Rong S, Woude GF. Hepatocyte growth factor/scatter
factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996;74:505-13.[Medline]
14
Lamszus K, Schmidt NO, Jin L, Laterra J, Zagzag D, Way D, et
al. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer 1998;75:19-28.[Medline]
15
Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P,
Anver M, et al. Diverse tumorigenesis associated with aberrant development in mice
overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 1997;94:701-6.[Abstract/Free Full Text]
16
Nabeshima K, Shimao Y, Sato S, Kataoka T, Moriyama T,
Kawano H, et al. Expression of c-Met correlates with grade of malignancy in human astrocytic
tumors: an immunohistochemical study. Histopathology 1997;31:436-43.[Medline]
17
Moriyama T, Kataoka H, Kawano H, Yokogami K, Nakano S,
Goya T, et al. Comparative analysis of expression of hepatocyte growth factor and its receptor,
c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett 1998;124:149-55.[Medline]
18
Hirose Y, Kojima M, Sagoh M, Murakami H, Yoshida K,
Shimazaki K, et al. Immunohistochemical examination of c-Met protein expression in astrocytic
tumors. Acta Neuropathol (Berl) 1998;95:345-51.[Medline]
19
Laterra J, Rosen E, Nam M, Ranganathan S, Fielding K,
Johnston P. Scatter factor/hepatocyte growth factor expression enhances human glioblastoma
tumorigenicity and growth. Biochem Biophys Res Commun 1997;235:743-7.[Medline]
20
Laterra J, Nam M, Rosen E, Rao JS, Lamszus K, Goldberg ID,
et al. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and
angiogenesis in vivo. Lab Invest 1997;76:565-77.[Medline]
21
Montgomery RA, Dietz HC. Inhibition of fibrillin 1 expression
using U1 snRNA as a vehicle for the presentation of antisense targeting sequence. Hum
Mol Genet 1997;4:519-25.
22
Zuker M. On finding all suboptimal foldings of an RNA
molecule. Science 1989;244:48-52.[Medline]
23
Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. Cold
Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989. p. 7.357.39.
24
Rosen EM, Laterra J, Joseph A, Jin L, Fuchs A, Way D, et al.
Scatter factor expression and regulation in human glial tumors. Int J Cancer 1996;67:248-55.[Medline]
25
Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of
proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.[Abstract]
26
Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of
human mn23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor
metastatic potential, colonization and enzymatic activity. Oncogene 1993;8:2325-33.[Medline]
27
Gunther B. On theories of biological similarity. Fortschr
Exp Theoret Biophys 1975;19:9-28.
28
Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in
histopathology. Histopathology 1990;17:489-503.[Medline]
29
Guthrie C, Patterson B. Spliceosomal snRNAs. Annu Rev
Genet 1988;22:387-419.[Medline]
30
Hamm J, Darzynkiewicz E, Tahara SM, Mattaj IW. The
trimethylguanosine cap structure of U1 snRNA is a component of a bipartite nuclear targeting
signal. Cell 1990;62:569-77.[Medline]
31
Liu Z, Batt DB, Carmichael GG. Targeted nuclear antisense
RNA mimics natural antisense-induced degradation of polyoma virus early RNA. Proc Natl
Acad Sci U S A 1994;91:4258-4262.[Abstract]
32
Boccaccio C, Gaudino G, Gambarotta G, Galimi F, Comoglio
PM. Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the
delayed-early response to HGF. J Biol Chem 1994;269:12846-51.[Abstract/Free Full Text]
33
Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande
Woude GF. Met expression and sarcoma tumorigenicity. Cancer Res 1993;53:5355-60.[Abstract]
34
Jeffers M, Rong S, Anver M, Vande Woude GF. Autocrine
hepatocyte growth factor/scatter factor-Met signaling induces transformation and the
invasive/metastastic phenotype in C127 cells. Oncogene 1996;13:853-6.[Medline]
35
Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G,
Kishida T, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997;21:11445-50.
36
Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M,
Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4)
for hepatocyte growth factor. Oncogene 1998;17:3045-54.[Medline]
37
Grant DS, Kleinman HK, Goldberg ID, Bhargava MM,
Nickoloff BJ, Kinsella JL, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993;90:1937-41.[Abstract]
38
Moriyama T, Kataoka H, Hamasuna R, Yokogami K, Uehara H,
Kawano H, et al. Up-regulation of vascular endothelial growth factor induced by hepatocyte
growth factor/scatter factor stimulation in human glioma cells. Biochem Biophys Res
Commun 1998;249:73-7.[Medline]
39
Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G,
Birchmeier W, et al. Extracellular proteolytic cleavage by urokinase is required for activation of
hepatocyte growth factor/scatter factor. EMBO J 1992;11:4825-33.[Abstract]
40
Kamiyama T, Une Y, Uchino J, Hamada J. Hepatocyte growth
factor enhances the invasion activity of human hepatocellular carcinoma cell lines. Int J
Oncol 1998;12:655-9.[Medline]
41
Fan S, Wang JA, Yuan RQ, Rockwell S, Andres J, Zlatapolskiy
A, et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by
DNA-damaging agents. Oncogene 1998;17:131-41.[Medline]
Manuscript received February 1, 1999;
revised June 29, 1999;
accepted July 13, 1999.
This article has been cited by other articles in HighWire Press-hosted journals:
-
Abounader, R., Laterra, J.
(2005). Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncol
7: 436-451
[Abstract]
-
Li, Y., Lal, B., Kwon, S., Fan, X., Saldanha, U., Reznik, T. E., Kuchner, E. B., Eberhart, C., Laterra, J., Abounader, R.
(2005). The Scatter Factor/Hepatocyte Growth Factor: c-Met Pathway in Human Embryonal Central Nervous System Tumor Malignancy. Cancer Res
65: 9355-9362
[Abstract]
[Full Text]
-
Zhang, S.-Z., Pan, F.-Y., Xu, J.-F., Yuan, J., Guo, S.-Y., Dai, G., Xue, B., Shen, W.-G., Wen, C.-J., Zhao, D.-H., Li, C.-J.
(2005). Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther
4: 1577-1584
[Abstract]
[Full Text]
-
Lal, B., Xia, S., Abounader, R., Laterra, J.
(2005). Targeting the c-Met Pathway Potentiates Glioblastoma Responses to {gamma}-Radiation. Clin Cancer Res
11: 4479-4486
[Abstract]
[Full Text]
-
Fan, X., Mikolaenko, I., Elhassan, I., Ni, X., Wang, Y., Ball, D., Brat, D. J., Perry, A., Eberhart, C. G.
(2004). Notch1 and Notch2 Have Opposite Effects on Embryonal Brain Tumor Growth. Cancer Res
64: 7787-7793
[Abstract]
[Full Text]
-
Shinomiya, N., Gao, C. F., Xie, Q., Gustafson, M., Waters, D. J., Zhang, Y.-W., Vande Woude, G. F.
(2004). RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and Survival. Cancer Res
64: 7962-7970
[Abstract]
[Full Text]
-
Wang, X., Le, P., Liang, C., Chan, J., Kiewlich, D., Miller, T., Harris, D., Sun, L., Rice, A., Vasile, S., Blake, R. A., Howlett, A. R., Patel, N., McMahon, G., Lipson, K. E.
(2003). Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther
2: 1085-1092
[Abstract]
[Full Text]
-
Shinomiya, N., Vande Woude, G. F.
(2003). Suppression of Met Expression: A Possible Cancer Treatment: Commentary re: S. J. Kim et al., Reduced c-Met Expression by an Adenovirus Expressing a c-Met Ribozyme Inhibits Tumorigenic Growth and Lymph Node Metastases of PC3-LN4 Prostate Tumor Cells in an Orthotopic Nude Mouse Model. Clin. Cancer Res., 14: 5161-5170, 2003.. Clin Cancer Res
9: 5085-5090
[Full Text]
-
Kim, S. J., Johnson, M., Koterba, K., Herynk, M. H., Uehara, H., Gallick, G. E.
(2003). Reduced c-Met Expression by an Adenovirus Expressing a c-Met Ribozyme Inhibits Tumorigenic Growth and Lymph Node Metastases of PC3-LN4 Prostate Tumor Cells in an Orthotopic Nude Mouse Model. Clin Cancer Res
9: 5161-5170
[Abstract]
[Full Text]
-
Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., Chen, J., Wang, X., Ruslim, L., Blake, R., Lipson, K. E., Ramphal, J., Do, S., Cui, J. J., Cherrington, J. M., Mendel, D. B.
(2003). A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo. Cancer Res
63: 7345-7355
[Abstract]
[Full Text]
-
Kunkel, P., Muller, S., Schirmacher, P., Stavrou, D., Fillbrandt, R., Westphal, M., Lamszus, K.
(2001). Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro-oncol
3: 82-88
[Abstract]
-
Brockmann, M. A., Papadimitriou, A., Brandt, M., Fillbrandt, R., Westphal, M., Lamszus, K.
(2003). Inhibition of Intracerebral Glioblastoma Growth by Local Treatment with the Scatter Factor/Hepatocyte Growth Factor-Antagonist NK4. Clin Cancer Res
9: 4578-4585
[Abstract]
[Full Text]
-
Jiang, W. G., Grimshaw, D., Martin, T. A., Davies, G., Parr, C., Watkins, G., Lane, J., Abounader, R., Laterra, J., Mansel, R. E.
(2003). Reduction of Stromal Fibroblast-induced Mammary Tumor Growth, by Retroviral Ribozyme Transgenes to Hepatocyte Growth Factor/Scatter Factor and its Receptor, c-MET. Clin Cancer Res
9: 4274-4281
[Abstract]
[Full Text]
-
Sattler, M., Pride, Y. B., Ma, P., Gramlich, J. L., Chu, S. C., Quinnan, L. A., Shirazian, S., Liang, C., Podar, K., Christensen, J. G., Salgia, R.
(2003). A Novel Small Molecule Met Inhibitor Induces Apoptosis in Cells Transformed by the Oncogenic TPR-MET Tyrosine Kinase. Cancer Res
63: 5462-5469
[Abstract]
[Full Text]
-
Herynk, M. H., Stoeltzing, O., Reinmuth, N., Parikh, N. U., Abounader, R., Laterra, J., Radinsky, R., Ellis, L. M., Gallick, G. E.
(2003). Down-Regulation of c-Met Inhibits Growth in the Liver of Human Colorectal Carcinoma Cells. Cancer Res
63: 2990-2996
[Abstract]
[Full Text]
-
Bannon, D. I., Abounader, R., Lees, P. S. J., Bressler, J. P.
(2003). Effect of DMT1 knockdown on iron, cadmium, and lead uptake in Caco-2 cells. Am. J. Physiol.
284: C44-50
[Abstract]
[Full Text]
-
Danilkovitch-Miagkova, A., Zbar, B.
(2002). Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest.
109: 863-867
[Full Text]
-
Walter, K. A., Hossain, M. A., Luddy, C., Goel, N., Reznik, T. E., Laterra, J.
(2002). Scatter Factor/Hepatocyte Growth Factor Stimulation of Glioblastoma Cell Cycle Progression through G1 Is c-Myc Dependent and Independent of p27 Suppression, Cdk2 Activation, or E2F1-Dependent Transcription. Mol. Cell. Biol.
22: 2703-2715
[Abstract]
[Full Text]
-
Takei, Y., Kadomatsu, K., Matsuo, S., Itoh, H., Nakazawa, K., Kubota, S., Muramatsu, T.
(2001). Antisense Oligodeoxynucleotide Targeted to Midkine, a Heparin-binding Growth Factor, Suppresses Tumorigenicity of Mouse Rectal Carcinoma Cells. Cancer Res
61: 8486-8491
[Abstract]
[Full Text]
-
Jiang, W. G., Grimshaw, D., Lane, J., Martin, T. A., Abounder, R., Laterra, J., Mansel, R. E.
(2001). A Hammerhead Ribozyme Suppresses Expression of Hepatocyte Growth Factor/Scatter Factor Receptor c-MET and Reduces Migration and Invasiveness of Breast Cancer Cells. Clin Cancer Res
7: 2555-2562
[Abstract]
[Full Text]
-
Cao, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., Wang, L.-M., Vande Woude, G. F.
(2001). Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. U. S. A.
98: 7443-7448
[Abstract]
[Full Text]
-
Tokunou, M., Niki, T., Eguchi, K., Iba, S., Tsuda, H., Yamada, T., Matsuno, Y., Kondo, H., Saitoh, Y., Imamura, H., Hirohashi, S.
(2001). c-MET Expression in Myofibroblasts : Role in Autocrine Activation and Prognostic Significance in Lung Adenocarcinoma. Am J Pathol
158: 1451-1463
[Abstract]
[Full Text]
-
Kuba, K., Matsumoto, K., Date, K., Shimura, H., Tanaka, M., Nakamura, T.
(2000). HGF/NK4, a Four-Kringle Antagonist of Hepatocyte Growth Factor, Is an Angiogenesis Inhibitor that Suppresses Tumor Growth and Metastasis in Mice. Cancer Res
60: 6737-6743
[Abstract]
[Full Text]
-
Kataoka, H., Hamasuna, R., Itoh, H., Kitamura, N., Koono, M.
(2000). Activation of Hepatocyte Growth Factor/Scatter Factor in Colorectal Carcinoma. Cancer Res
60: 6148-6159
[Abstract]
[Full Text]
-
Bowers, D. C., Fan, S., Walter, K. A., Abounader, R., Williams, J. A., Rosen, E. M., Laterra, J.
(2000). Scatter Factor/Hepatocyte Growth Factor Protects against Cytotoxic Death in Human Glioblastoma via Phosphatidylinositol 3-Kinase- and AKT-dependent Pathways. Cancer Res
60: 4277-4283
[Abstract]
[Full Text]
-
LaVail, M. M., Yasumura, D., Matthes, M. T., Drenser, K. A., Flannery, J. G., Lewin, A. S., Hauswirth, W. W.
(2000). Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy. Proc. Natl. Acad. Sci. U. S. A.
97: 11488-11493
[Abstract]
[Full Text]
 |
|